Drugs / MSB11455
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03251248 | Aug 2017 → May 2018 | — | Fresenius Kabi SwissBioSim GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03251339 | Aug 2017 → Feb 2018 | — | Fresenius Kabi SwissBioSim GmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSB11455 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03251248 ↗ |
| Route | Subcutaneous | “Subjects received a single subcutaneous dose of MSB11455 or the reference product (both 6 mg/0.6 mL) on Day 1 of each study period.” PMID 32660769 ↗ Jul 2020 |